Alexion Pharmaceuticals welcomes new CCO, makes other managerial changes
May 23, 2017Alexion Pharmaceuticals has announced big changes to its executive leadership team. Brian Goff is joining Alexion as Chief Commercial Officer, effective June 1, 2017.
As the company said in its press release, Goff will lead all commercial operations globally with responsibility for country operations in each of Alexion’s affiliates in North America, EMEA, Japan, Asia Pacific, and Latin America. He succeeds Carsten Thiel who is leaving the company to pursue new opportunities effective June 1, 2017.
Dave Anderson, Chief Financial Officer, will resign his position at the end of August. Also, Martin Mackay, Executive Vice President, Head of Research & Development will be retiring from Alexion at the end of 2017.
A search for a new CFO and a new Head of R&D is underway with Spencer Stuart, the company said.
The company also announced that Clare Carmichael, Executive Vice President, Chief Human Resources Officer, will be leaving the Company to pursue new opportunities effective June 1, 2017. Recruiting is underway for a new Head of Human Resources, as well.
Ludwig Hantson, Alexion’s Chief Executive Officer, stated, “We are delighted to welcome Brian to Alexion as our new Chief Commercial Officer and look forward to his leadership in developing and executing our strategies for long-term growth as we focus on creating value for all stakeholders. He brings to Alexion the expertise and proven track record that will help us continue to build on our global leadership position, as well as a passion for developing talent and cultivating a high-performing culture. At the same time, we thank Carsten for his many contributions to Alexion’s success over the past three years. He has played a critical role in bringing Alexion’s innovative therapies to patients with rare and devastating diseases around the world and establishing a solid foundation for the future.”
